阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌患者的效果

Effects of Apatinib combined with FOLFOX chemotherapy in treatment of patients with advanced gastric cancer

目的:观察阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌患者的效果。方法:选取2021年6月至2023年6月该院收治的80例晚期胃癌患者进行前瞻性研究,按照随机数字表法将其分为观察组和对照组各40例。对照组采用FOLFOX化疗方案治疗,观察组在对照组基础上联合阿帕替尼治疗,两组均治疗2个周期。比较两组临床疗效,治疗前后肿瘤标志物[糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、糖类抗原72-4(CA72-4)、糖类抗原125(CA125)]水平、生命质量[欧洲癌症研究和治疗组织生活质量核心问卷量表(EORTC QLQ-C30)]评分,以及不良反应发生率。结果:观察组疾病控制率(DCR)为92.50%(37/40),高于对照组的72.50%(29/40),差异有统计学意义(P<0.05);治疗后,观察组CEA、CA19-9、CA72-4、CA125水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组EORTC QLQ-C30功能量表、总健康状况量表评分均高于对照组,症状量表评分低于对照组,差异有统计学意义(P<0.05);两组口腔黏膜炎、骨髓抑制、肝功能损害、恶心呕吐等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌患者可提高DCR,降低肿瘤标志物水平,改善生命质量,效果优于单纯FOLFOX化疗方案治疗。

Objective:To observe effects of Apatinib combined with FOLFOX chemotherapy in treatment of patients with advanced gastric cancer.Methods:A prospective study was conducted on 80 patients with advanced gastric cancer admitted to the hospital from June 2021 to June 2023.According to the random number table method,they were divided into observation group and control group,40 cases in each group.The control group was treated with FOLFOX chemotherapy,while the observation group was treated with Apatinib on the basis of that of the control group.Both groups were treated for 2 cycles.The clinical efficacy,the tumor markers[carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),carbohydrate antigen 72-4(CA72-4),carbohydrate antigen 125(CA125)]levels,the quality of life[European organization for research and treatment of cancer quality of life core questionnaire scale(EORTC QLQ-C30)]scores before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the observation group was 92.50%(37/40),which was higher than 72.50%(29/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,CA19-9,CA72-4 and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the scores of functional scale and total health status scale of EORTC QLQ-C30 in the observation group were higher than those in the control group,the scores of symptom scale were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as oral mucositis,bone marrow suppression,liver function damage,nausea and vomiting between the two groups(P>0.05).Conclusions:Apatinib combined with FOLFOX chemotherapy in the treatment of the patients with advanced gastric cancer can improve the DCR,reduce the levels of tumor markers,and improve the quality of life.Moreover,it is superior to simple FOLFOX chemotherapy.